Go Pro
→ CODE RED: AI Meltdown Imminent? (From Paradigm Press) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
$0.19
-6.5%		$0.24
$0.19
▼
$2.88
$5.79M1.1912.48 million shs1.87 million shs
Provectus Biopharmaceuticals, Inc. stock logo
PVCT
Provectus Biopharmaceuticals
$0.05
-0.9%		$0.06
$0.04
▼
$0.09
$22.91M0.86224,151 shs126,689 shs
Sernova Biotherapeutics Inc. stock logo
SEOVF
Sernova Biotherapeutics
$0.06
+3.1%		$0.08
$0.06
▼
$0.15
$24.13M0.8658,666 shs410,750 shs
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
$0.34
-2.6%		$0.64
$0.29
▼
$2.57
$23.05M1.07750,572 shs381,048 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
-3.19%-6.44%-19.96%-34.86%-92.57%
Provectus Biopharmaceuticals, Inc. stock logo
PVCT
Provectus Biopharmaceuticals
+3.97%-1.26%-8.79%-17.42%-17.91%
Sernova Biotherapeutics Inc. stock logo
SEOVF
Sernova Biotherapeutics
-11.43%-17.33%-22.50%-33.48%-52.96%
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
-4.12%+4.65%-56.03%-63.98%-81.03%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
$0.19
-6.5%		$0.24
$0.19
▼
$2.88
$5.79M1.1912.48 million shs1.87 million shs
Provectus Biopharmaceuticals, Inc. stock logo
PVCT
Provectus Biopharmaceuticals
$0.05
-0.9%		$0.06
$0.04
▼
$0.09
$22.91M0.86224,151 shs126,689 shs
Sernova Biotherapeutics Inc. stock logo
SEOVF
Sernova Biotherapeutics
$0.06
+3.1%		$0.08
$0.06
▼
$0.15
$24.13M0.8658,666 shs410,750 shs
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
$0.34
-2.6%		$0.64
$0.29
▼
$2.57
$23.05M1.07750,572 shs381,048 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
-3.19%-6.44%-19.96%-34.86%-92.57%
Provectus Biopharmaceuticals, Inc. stock logo
PVCT
Provectus Biopharmaceuticals
+3.97%-1.26%-8.79%-17.42%-17.91%
Sernova Biotherapeutics Inc. stock logo
SEOVF
Sernova Biotherapeutics
-11.43%-17.33%-22.50%-33.48%-52.96%
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
-4.12%+4.65%-56.03%-63.98%-81.03%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
2.50
Moderate Buy$9.004,636.84% Upside
Provectus Biopharmaceuticals, Inc. stock logo
PVCT
Provectus Biopharmaceuticals
0.00
N/AN/AN/A
Sernova Biotherapeutics Inc. stock logo
SEOVF
Sernova Biotherapeutics
0.00
N/AN/AN/A
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
2.13
Hold$2.67688.95% Upside

Current Analyst Ratings Breakdown

Latest AIM, TCRX, SEOVF, and PVCT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/8/2026
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
9/8/2026
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy ➝ Neutral$1.00
9/2/2026
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy ➝ Neutral$1.00
9/2/2026
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
Lifesci Capital logo
Lifesci Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
8/13/2026
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
Benchmark Co. logo
Benchmark
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/12/2026
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
7/17/2026
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
(Data available from 9/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
$90K64.26N/AN/A($2.99) per share-0.06
Provectus Biopharmaceuticals, Inc. stock logo
PVCT
Provectus Biopharmaceuticals
$340K65.39N/AN/A($0.02) per share-2.65
Sernova Biotherapeutics Inc. stock logo
SEOVF
Sernova Biotherapeutics
N/AN/AN/AN/A($0.05) per shareN/A
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
$10.32M2.22N/AN/A$2.16 per share0.16
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
-$13.96M-$24.68N/AN/AN/A-15,021.05%N/A-143.02%N/A
Provectus Biopharmaceuticals, Inc. stock logo
PVCT
Provectus Biopharmaceuticals
-$5.43MN/AN/AN/AN/AN/AN/A-599.37%N/A
Sernova Biotherapeutics Inc. stock logo
SEOVF
Sernova Biotherapeutics
-$11.24M-$0.04N/AN/AN/AN/AN/A-926.94%N/A
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
-$129.77M-$0.91N/AN/AN/A-1,655.35%-108.72%-54.47%11/11/2026 (Estimated)

Latest AIM, TCRX, SEOVF, and PVCT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
9/10/2026Q3 2026
Sernova Biotherapeutics Inc. stock logo
SEOVF
Sernova Biotherapeutics
-$0.0050-$0.01-$0.0050-$0.01N/AN/A
8/12/2026Q2 2026
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
-$0.2534-$0.23+$0.0234-$0.23$1.88 million$1.05 million
8/7/2026Q2 2026
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
N/A-$0.43N/A-$0.43N/A$0.03 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
N/AN/AN/AN/AN/A
Provectus Biopharmaceuticals, Inc. stock logo
PVCT
Provectus Biopharmaceuticals
N/AN/AN/AN/AN/A
Sernova Biotherapeutics Inc. stock logo
SEOVF
Sernova Biotherapeutics
N/AN/AN/AN/AN/A
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
N/A
2.11
2.11
Provectus Biopharmaceuticals, Inc. stock logo
PVCT
Provectus Biopharmaceuticals
N/A
0.18
0.18
Sernova Biotherapeutics Inc. stock logo
SEOVF
Sernova Biotherapeutics
N/A
0.14
0.14
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
0.31
3.37
3.37

Institutional Ownership

CompanyInstitutional Ownership
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
12.02%
Provectus Biopharmaceuticals, Inc. stock logo
PVCT
Provectus Biopharmaceuticals
0.05%
Sernova Biotherapeutics Inc. stock logo
SEOVF
Sernova Biotherapeutics
N/A
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
82.83%

Insider Ownership

CompanyInsider Ownership
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
0.95%
Provectus Biopharmaceuticals, Inc. stock logo
PVCT
Provectus Biopharmaceuticals
20.20%
Sernova Biotherapeutics Inc. stock logo
SEOVF
Sernova Biotherapeutics
N/A
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
6.25%
CompanyEmployeesShares OutstandingFree FloatOptionable
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
2130.44 million30.15 millionNot Optionable
Provectus Biopharmaceuticals, Inc. stock logo
PVCT
Provectus Biopharmaceuticals
4420.28 million335.38 millionNot Optionable
Sernova Biotherapeutics Inc. stock logo
SEOVF
Sernova Biotherapeutics
N/A377.64 millionN/ANot Optionable
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
14267.78 million63.54 millionNot Optionable

Recent News About These Companies

TScan Therapeutics consensus price target decreased by 55.56% to $2.72
September 16, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/tscan-therapeutics-consensus-price-target-decreased-by-55-56-to-2-72/ar-AA2cjuKv
Wedbush downgrades TScan Therapeutics (TCRX) to neutral from outperform
September 3, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/wedbush-downgrades-tscan-therapeutics-tcrx-to-neutral-from-outperform/ar-AA2bwA9B
TScan Therapeutics Reorganizes To Focus On Solid Tumor Program; To Cut 75% Jobs; Stock Tumbles 11%
September 2, 2026  |  rttnews.comhttps://www.rttnews.com/3687878/tscan-therapeutics-reorganizes-to-focus-on-solid-tumor-program-to-cut-75-jobs-stock-tumbles-11.aspx
TScan Therapeutics cuts workforce by 75% and shifts focus to solid tumor program
September 2, 2026  |  msn.comhttps://www.msn.com/en-us/science/general/tscan-therapeutics-cuts-workforce-by-75-and-shifts-focus-to-solid-tumor-program/ar-AA2bqfIn
TScan Reorganizes Pipeline Priorities, Implements Workforce Reduction
September 2, 2026  |  benzinga.comhttps://www.benzinga.com/news/health-care/26/09/61580674/tscan-reorganizes-pipeline-priorities-implements-workforce-reduction
TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors
September 2, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/02/3354974/0/en/tscan-therapeutics-announces-strategic-reorganization-to-focus-on-in-vivo-cell-therapy-for-solid-tumors.html
Analysts Offer Insights on Healthcare Companies: Immix Biopharma (IMMX), TScan Therapeutics (TCRX) and enGene Holdings (ENGN)
August 13, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/IMMX/pressreleases/3830638/analysts-offer-insights-on-healthcare-companies-immix-biopharma-immx-tscan-therapeutics-tcrx-and-engene-holdings-engn/
TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Misses Revenue Estimates
August 12, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2973293/tscan-therapeutics-inc-tcrx-reports-q2-loss-misses-revenue-estimates?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_4-2973293
TScan Therapeutics Reports First Patient Dosed in Phase 3 ALLOHA-2 Study and Second-Quarter 2026 Results
August 12, 2026  |  quiverquant.comQ
TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 12, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/12/3343490/0/en/tscan-therapeutics-reports-second-quarter-2026-financial-results-and-provides-corporate-update.html
TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2™, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies
July 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/29/3335095/0/en/tscan-therapeutics-announces-first-patient-dosed-in-phase-3-alloha-2-a-pivotal-trial-evaluating-tsc-101-in-patients-with-heme-malignancies.html
TScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
June 24, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/24/3316713/0/en/tscan-therapeutics-to-participate-in-the-h-c-wainwright-4th-annual-cell-therapy-virtual-conference.html
TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic ...
June 23, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/tscan-therapeutics-announces-positive-initial-data-from-cohort-c-of-ongoing-alloha-phase-1-study-evaluating-tsc-101-in-patients-with-heme-malignancies-undergoing-allogeneic-hematopoietic-cell-1036264745
TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation
June 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/22/3315162/0/en/tscan-therapeutics-announces-positive-initial-data-from-cohort-c-of-ongoing-alloha-phase-1-study-evaluating-tsc-101-in-patients-with-heme-malignancies-undergoing-allogeneic-hematop.html
Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies
June 3, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260603703141/en/cellares-and-tscan-therapeutics-announce-agreement-to-evaluate-automated-manufacturing-of-tsc-101-for-patients-with-hematologic-malignancies/
TScan Therapeutics, Inc. (TCRX) Reports Q1 2026 Results With Improved Net Loss
June 2, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/tscan-therapeutics-inc-tcrx-reports-q1-2026-results-with-improved-net-loss-1773515/
TScan Therapeutics Expands Authorized Shares After Stockholder Vote
May 22, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/tscan-therapeutics-expands-authorized-shares-after-stockholder-vote?utm_source=marketbeat.com&utm_medium=referral
TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue Estimates
May 6, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2915585/tscan-therapeutics-inc-tcrx-reports-q1-loss-lags-revenue-estimates?cid=cs-stocknewsapi-ft-tale_of_the_tape|yseop_template_4-2915585
TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 6, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/06/3288637/0/en/tscan-therapeutics-reports-first-quarter-2026-financial-results-and-provides-corporate-update.html
TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual Meeting
April 27, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/27/3282046/0/en/tscan-therapeutics-announces-upcoming-presentation-at-the-american-society-of-gene-and-cell-therapy-29th-annual-meeting.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
NVIDIA logo displayed on a wall inside a data center with server racks and monitors visible.
NVIDIA’s Hugging Face Deal Raises a Bigger Question About Its AI Moat Now
By Jeffrey Neal Johnson | September 3, 2026
Block logo overlaid on a coffee shop counter with a Square point-of-sale terminal and card reader.
Block Makes a Federal Trust Bank Move That Could Reshape Its Fintech Model
By Jeffrey Neal Johnson | September 11, 2026
Apple Inc. logo displayed against a curved white LED wall backdrop.
Apple Is Quietly Building an AI Advantage Few Expected
By Jeffrey Neal Johnson | September 17, 2026
A rocket launches from a tower amid flames and smoke, with the SpaceX logo displayed beside it.
SpaceX and NVIDIA Want to Put AI Data Centers in Orbit
By Sam Quirke | September 20, 2026
Car dashboard display showing the BlackBerry logo with connected vehicle icons for security, cloud, and automotive systems.
BlackBerry Shifts Gears With Coretura Deal
By Jeffrey Neal Johnson | September 25, 2026
AIM ImmunoTech stock logo

AIM ImmunoTech NYSEAMERICAN:AIM

$0.19 -0.01 (-6.49%)
Closing price 04:10 PM Eastern
Extended Trading
$0.19 0.00 (-0.05%)
As of 05:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.

Provectus Biopharmaceuticals stock logo

Provectus Biopharmaceuticals OTCMKTS:PVCT

$0.05 0.00 (-0.91%)
As of 03:59 PM Eastern

Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes in the United States. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis. It is also developing oral formulations for adult solid tumor cancers, as well as refractory and relapsed pediatric, and other blood cancers comprising leukemias; PV-10 for the treatment of relapsed and refractory pediatric solid tumor cancers; and other formulations for the treatment of cutaneous canine cancers and healing of full-thickness cutaneous wounds. In addition, the company develops oral and intranasal formulations for the treatment of severe acute respiratory syndrome coronavirus 2; gram-positive and gram-negative bacterial infections; oral bacterial infections; and fungal infections, as well as vertebrate development, wound healing, and tissue regrowth. It has collaboration agreement with Bascom Palmer Eye Institute; and University of Miami. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was founded in 2002 and is based in Knoxville, Tennessee.

Sernova Biotherapeutics stock logo

Sernova Biotherapeutics OTCMKTS:SEOVF

$0.06 +0.00 (+3.06%)
As of 03:54 PM Eastern

Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection. Its Cell Pouch is a novel implantable and scalable medical device which forms a natural environment in the body for the housing and long-term survival and function of therapeutic cells, which release necessary proteins or factors missing from the body to treat chronic diseases as an alternative to daily administration of drugs. Sernova Corp. has a research agreement with the University of Miami to advance the development of Conformal Coating Technology in combination with therapeutic cells within Cell Pouch. Sernova Corp. was incorporated in 1998 and is headquartered in London, Canada.

TScan Therapeutics stock logo

TScan Therapeutics NASDAQ:TCRX

$0.34 -0.01 (-2.58%)
Closing price 04:00 PM Eastern
Extended Trading
$0.34 +0.00 (+0.29%)
As of 04:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas